Skip to content
OpenCapital
Get started

Charles River Laboratories CRL Share-based compensation expense related to employee stock plans

Share-based compensation expense related to employee stock plans at other companies

Bio-Rad Laboratories logo
Bio-Rad LaboratoriesBIO
——
Thermo Fisher Scientific logo
Thermo Fisher ScientificTMO
——
GE HealthCare Technologies logo
GE HealthCare TechnologiesGEHC
——

Other financials

Income statement

See full
Revenue$995.8M+1.2%
Gross profit$349.0M-3.5%
Operating income$119.9M+60.6%
Net income-$14.8M-158%
EPS (diluted)-$0.30-160%

Balance sheet

See full
Cash & equivalents$198.2M-14.5%
Total debt$3.1B+1.9%
Total equity$2.9B-7.9%
Total assets$7.7B+2.0%

Cash flow

See full
Operating cash flow$41.1M-76.1%
CapEx$55.9M-5.8%
Free cash flow-$14.8M-113%

Valuation

See full
Market cap$8.91B+10.3%
Enterprise value$11.79B+8.5%
P/S2.2×+0.2×

Profitability

See full
Gross margin84.7%—
Operating margin13%-2.4pp
Net margin-4.6%—
FCF margin9.7%-4.3pp

Returns & leverage

See full
Return on equity-6%—
Debt / equity1×+0.1×
Current ratio1.4×-0.1×

Where this comes from

Reported directly by Charles River Laboratories in its filing.

Tagged under the XBRL concept us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue.

The official record: Charles River Laboratories’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Charles River Laboratories's share-based compensation expense related to employee stock plans.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Charles River Laboratories's share-based compensation expense related to employee stock plans?
Charles River Laboratories (CRL) reported share-based compensation expense related to employee stock plans of $22.38M in Q1 2026.
How has Charles River Laboratories's share-based compensation expense related to employee stock plans changed year-over-year?
Charles River Laboratories's share-based compensation expense related to employee stock plans increased by 70.4% year-over-year, from $13.14M to $22.38M.
What is the long-term trend for Charles River Laboratories's share-based compensation expense related to employee stock plans?
Over 2 years (2023 to 2025), Charles River Laboratories's share-based compensation expense related to employee stock plans has grown at a -0.7% compound annual growth rate (CAGR), from $72.05M to $71.08M.